Andrew Hooker

Dr Andy Hooker has global responsibility for analytical, formulation and bioprocess development, GMP biomanufacturing and supply chain activities, supporting both Clinical Development and Commercial Life Cycle Management. He has held a number of senior CMC positions with various pharmaceutical companies, including Ipsen Bioinnovation, Syntaxin Ltd; and UCB, Slough, where he successfully supported the CMC regulatory commercial approval of Cimzia, in both the US and EU, for the treatment of Crohns Disease and Rheumatoid Arthritis. Andy was also previously a CMC Group Leader with Pfizer R&D in the UK, supporting the progression of oncology monoclonal antibody candidates throughout early clinical development. He has also held the position of Head of Analytical Services with the proteomics-company Oxford GlycoSciences. Andy has a PhD in Biochemistry from the University of Kent and a BSc (Hons) in Biochemistry from the University of East Anglia.